These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12518207)

  • 1. Goldenhar syndrome and hereditary tyrosinemia type 1.
    Al-Sayed MA; Asmari AM; Rashed MS
    Saudi Med J; 2002 Dec; 23(12):1527-31. PubMed ID: 12518207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Goldenhar syndrome and hereditary tyrosinemia type 1.
    Al-Sayed MA; Al-Asmari AM; Rashed MS
    Neurosciences (Riyadh); 2003 Jan; 8(1):55-9. PubMed ID: 23648989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathophysiology and treatment of hereditary tyrosinemia type 1.
    Grompe M
    Semin Liver Dis; 2001 Nov; 21(4):563-71. PubMed ID: 11745044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Goldenhar syndrome (oculoauriculovertebral dysplasia): report of one case.
    Ng YY; Hu JM; Su PH; Chen JY; Yang MS; Chen SJ
    Acta Paediatr Taiwan; 2006; 47(3):142-5. PubMed ID: 17078468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Richner-Hanhart syndrome (tyrosinemia II): early diagnosis of an incomplete presentation with unusual findings.
    Viglizzo GM; Occella C; Bleidl D; Rongioletti F
    Pediatr Dermatol; 2006; 23(3):259-61. PubMed ID: 16780475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical, biochemical and molecular characteristics in 11 Czech children with tyrosinemia type I].
    Vondrácková A; Tesarová M; Magner M; Docekalová D; Chrastina P; Procházkova D; Zeman J; Honzík T
    Cas Lek Cesk; 2010; 149(9):411-6. PubMed ID: 21117323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal presentation of a rare metabolic liver disease.
    David JJ; Tullu MS; Rathi P; Sawalakhe N; Ghildiyal RG
    Trop Gastroenterol; 2008; 29(4):229-31. PubMed ID: 19323095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment.
    van Spronsen FJ; Bijleveld CM; van Maldegem BT; Wijburg FA
    J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):90-3. PubMed ID: 15625434
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tyrosinemia type II. Case report].
    Benatiya AI; Bouayed MA; Touiza E; Daoudi K; Bhalil S; Elmesbahi I; Tahri H
    Bull Soc Belge Ophtalmol; 2005; (296):57-61. PubMed ID: 16050420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recommendations and management of type I hereditary or hepatorenal tyrosinemia].
    Couce ML; Aldámiz-Echevarría L; Baldellou A; Blasco J; Bueno MA; Dalmau J; De La Vega A; Del Toro M; Díaz C; Lama R; Leao E; Marrero M; Navas VM; Pintos G
    An Pediatr (Barc); 2010 Nov; 73(5):279.e1-4. PubMed ID: 20813594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [One case of hereditary tyrosinemia type I].
    Huang YL; Li XJ; Luo XP; Wei H; Song YY
    Zhonghua Er Ke Za Zhi; 2003 Apr; 41(4):309. PubMed ID: 14754550
    [No Abstract]   [Full Text] [Related]  

  • 12. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
    Koelink CJ; van Hasselt P; van der Ploeg A; van den Heuvel-Eibrink MM; Wijburg FA; Bijleveld CM; van Spronsen FJ
    Mol Genet Metab; 2006 Dec; 89(4):310-5. PubMed ID: 17008115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Liver failure with coagulopathy in an infant with tyrosinemia].
    Nussinovitch M; Campino G; Shapira R; Voluvitz B; Amir J
    Harefuah; 2001 Jul; 140(7):578-9, 680. PubMed ID: 11481954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis of hereditary tyrosinemia type I: clinical study of ten patients].
    Li XY; DU ML; Zhuang SQ
    Zhonghua Er Ke Za Zhi; 2006 Jun; 44(6):470-1. PubMed ID: 16836864
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of 2-[2-nitro-4-(trifluoromethyl)benzoyl]- cyclohexane-1,3-dione metabolites in urine of patients suffering from tyrosinemia type I with the use of 1H and 19F NMR spectroscopy.
    Szczeciński P; Lamparska D; Gryff-Keller A; Gradowska W
    Acta Biochim Pol; 2008; 55(4):749-52. PubMed ID: 19039335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Goldenhar syndrome (case report)].
    Kuakuvi NK; Sanokho A; Senghor G; Sow D; Sarr M
    Dakar Med; 1979; 24(4):373-6. PubMed ID: 544217
    [No Abstract]   [Full Text] [Related]  

  • 17. [Goldenhar's oculoauricular dysplasia].
    Săninoiu M
    Oftalmologia; 1991; 35(3-4):33-6. PubMed ID: 1845441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Goldenhar syndrome (a case report).
    Kulkarni V; Shah MD; Parikh A
    J Postgrad Med; 1985 Jul; 31(3):177-9. PubMed ID: 4087222
    [No Abstract]   [Full Text] [Related]  

  • 19. [THE DIFFICULTY IN DIAGNOSING OF RARE FORMS OF CONGENITAL DISORDERS OF AMINO ACID METABOLISM IN INFANTS (HEREDITARY TYROSINEMIA)].
    Melnikova NI; Kartseva EV; Kirsanov AS; Strogonov IA; Ageeva LN; Kharitonova GD; Olhova EB; Belyaeva TY
    Anesteziol Reanimatol; 2015; 60(3):16-9. PubMed ID: 26415289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic tyrosinemias.
    Scott CR
    Am J Med Genet C Semin Med Genet; 2006 May; 142C(2):121-6. PubMed ID: 16602095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.